What’s The Upside Potential For Tilray Brands?

Tilray Brands (NASDAQ: TLRY) stock has already surged 2x in the past month following reports that the Trump administration is considering marijuana reclassification, demonstrating the market’s recognition of this transformational catalyst. But how big could this opportunity truly be for Tilray? Under a Schedule III reclassification scenario, Tilray’s revenues could double over the next three years while valuation multiples expand meaningfully as regulatory risks diminish and institutional participation increases. In this analysis, we focus on the upside potential for Tilray, which could be massive – potentially 5x from current levels.

The transformational impact of regulatory reform on revenue growth, operational efficiency, and market valuation may create one of the most compelling risk-reward opportunities in the cannabis sector, as we discuss in detail in the sections below. That being said, if you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 91% since its inception. Also, see – UNH Stock To $600?

Image by Jaroslav Moravcik from Pixabay

Revenue Growth Projections: The Schedule III Catalyst

Market Foundation and Growth Drivers

The cannabis industry provides a strong growth foundation, with legal sales projected to see significant growth in the coming years. The global legal marijuana market is expected to grow at 25.4% CAGR (Grand View Research). Under Schedule III reclassification, these growth rates could accelerate significantly due to enhanced legitimacy, banking access, and institutional participation.

Under Schedule III reclassification, Tilray could potentially achieve a doubling of revenues from $821 million to approximately $1.65 billion over the next three years. This 2x growth trajectory reflects the compound impact of regulatory reform catalysts working together:

• Tax savings from Section 280E elimination improving operational efficiency
• Enhanced banking access and institutional investment enabling expansion capital
• Interstate commerce opportunities unlocking U.S. market potential
• International expansion leveraging established presence in over 20 countries
• Medical cannabis market legitimization driving prescription growth

Valuation Multiple Expansion Analysis

Current vs. Target Valuation Framework

TLRY currently trades at 1.8x trailing revenues, significantly below the broader market’s 3.2x multiple due to regulatory uncertainty. Under successful Schedule III reclassification, multiple expansion to 5.0x is justified by:

• Regulatory risk elimination removing federal scheduling uncertainty
• Institutional participation as barriers lower and stigma decreases
• Operational efficiency gains from tax savings and banking access
• Growth premium warranting growth-stock rather than distressed asset multiples

In fact, some other cannabis stocks, such as Cronos trades at over 7 times trailing revenues, thanks to its backing from Altria.

Valuation Scenario

• Target Scenario: 5.0x multiple on $1.65B revenues
• Target valuation: $8.25 billion vs. current $1.6 billion
• Upside potential: over 400%

The doubling of revenues combined with multiple expansion from regulatory normalization creates a compelling value proposition for investors positioned ahead of potential policy changes.

Growth-Limiting Risk Factors

• Policy Uncertainty: Trump characterized the Schedule III decision as “not so much a done deal” and “a very complicated subject,” highlighting potential delays or implementation complexity.
• Jurisdictional Conflicts: State-federal regulatory misalignment could limit interstate commerce and operational efficiency despite federal reclassification.
• Industry Consolidation: Well-capitalized competitors, including traditional pharmaceutical and consumer goods companies, could pressure market share as barriers to entry decrease.
• Market Saturation: Rapid industry expansion may create oversupply conditions, particularly in mature markets, compressing pricing power.
• Capital Investment Requirements: Aggressive expansion will demand significant capital, potentially diluting shareholders or increasing debt burdens.
• International Complexity: While European opportunities exist, navigating diverse regulatory frameworks presents execution challenges.
• Scaling Challenges: Rapid growth could compromise quality control or regulatory compliance, particularly critical for medical cannabis products.
• Economic Cycle Exposure: Cannabis stocks exhibit high market sensitivity, with TLRY previously declining 97.6% during the 2022 inflation crisis versus 25.4% for the S&P 500.
• Interest Rate Impact: Rising rates could negatively affect growth stock valuations and increase expansion financing costs.

The Verdict

Schedule III reclassification creates a transformational opportunity for Tilray, with revenue doubling potential to $1.65 billion and valuation multiple expansion supporting 5x stock appreciation. The convergence of tax relief, banking access, institutional investment, and international expansion creates an asymmetric risk-reward profile strongly favoring investors willing to accept regulatory and execution uncertainty for extraordinary upside potential.

This analysis is purely focused on the upside potential associated with a potential Schedule III reclassification. While we have highlighted the risks, including regulatory and execution uncertainty, it is crucial for investors to remember that Tilray stock has a history of significant downturns, including losing nearly all of its value back in 2022. The past performance of the stock serves as a stark reminder that while the potential for extraordinary gains exists, so does the risk of substantial losses.

Now, we apply a risk assessment framework while constructing Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates